ERBB2 and breast carcinoma: Although maytansine monotherapy was too toxic, when its analog, DM, was linked to trastuzumab, the resulting ADC, T-DM1, offered a targeted and safer delivery system for the potent chemotherapy to treat HER2+ breast cancer.